Fig. 3.

Clinical outcomes on ICIs-based treatment. a Progression-free survival (PFS) from ICIs therapy initiation for the entire cohort. Dotted lines indicate 95% confidence intervals. b Group A: combination with chemotherapy; Group B: including monotherapy (n = 5), combination with anti-angiogenesis (n = 3), combination with chemotherapy plus anti-angiogenesis (n = 1), or combination with chemotherapy plus HER2-targeting drugs (n = 1). c Group C: Patients received ICIs as first-line treatment; Group D: Patients received ICIs as second or later-line treatment. d Group 1: Patients received ICIs before EGFR/HER2-targeting drugs; Group 2: Patients received ICIs after EGFR/HER2-targeting drugs; Group 3: patients never treated with EGFR/HER2-targeting drugs until the follow-up end date